Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sawai Group Holdings CoSWGHF 53 3-Year EBITDA Growth Rate is 2.40% as of Mar. 2026, which is at its 10-year median of 2.40. GuruFocus rates SWGHF with a GF Score™ of 53/100 and a GF Value™ of $15.98. The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Sawai Group Holdings Co ranks worse than 62.61% on this metric.
During the past 12 months, Sawai Group Holdings Co's average EBITDA Per Share Growth Rate was 76.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sawai Group Holdings Co was 2.40% per year. The lowest was 2.40% per year. And the median was 2.40% per year.
Sawai Group Holdings Co (OTCPK:SWGHF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sawai Group Holdings Co 3-Year EBITDA Growth Rate Related Terms
SWGHF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sawai Group Holdings Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sawai Group Holdings Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sawai Group Holdings Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sawai Group Holdings Co's 3-Year EBITDA Growth Rate falls into.
Sawai Group Holdings Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.40% mean?
Sawai Group Holdings Co (SWGHF) has a 3-Year EBITDA Growth Rate of 2.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sawai Group Holdings Co and its competitors. This is near median its historical median of 2.40. Over the past decade, Sawai Group Holdings Co's 3-Year EBITDA Growth Rate has ranged from 2.40 to 2.40. According to the industry distribution chart, Sawai Group Holdings Co ranks #509 out of 813 companies in the Drug Manufacturers industry, placing it in the top 62.6%.
Is Sawai Group Holdings Co's 3-Year EBITDA Growth Rate too high?
Sawai Group Holdings Co's current 3-Year EBITDA Growth Rate of 2.40% is near median its 10-year median of 2.40. Over the past 10 years, this metric has ranged from a low of 2.40 to a high of 2.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Sawai Group Holdings Co's value of 2.40% is 72.7% below this industry median. Based on the distribution chart, Sawai Group Holdings Co ranks #509 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sawai Group Holdings Co has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Sawai Group Holdings Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sawai Group Holdings Co ranks #509 out of 813 companies for 3-Year EBITDA Growth Rate. This places Sawai Group Holdings Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Sawai Group Holdings Co's value of 2.40% is 72.7% below this benchmark. Historically, Sawai Group Holdings Co's own 3-Year EBITDA Growth Rate has ranged from 2.40 to 2.40 over the past decade. While the company's 10-year median is 2.40 vs. the industry median of 8.80, Sawai Group Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sawai Group Holdings Co's current 3-Year EBITDA Growth Rate of 2.40% is 72.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sawai Group Holdings Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sawai Group Holdings Co's current 3-Year EBITDA Growth Rate is 2.40%, which is near median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sawai Group Holdings Co stock overvalued right now?
Sawai Group Holdings Co (SWGHF) has a current 3-Year EBITDA Growth Rate of 2.40%. The stock's GF Value™ is $15.98, compared to a current price of $11.52 — trading 27.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 2.40%, which is near median its 10-year median of 2.40 and 72.7% below the Drug Manufacturers industry median of 8.80. Sawai Group Holdings Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sawai Group Holdings Co (SWGHF), the current 3-Year EBITDA Growth Rate is 2.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sawai Group Holdings Co (SWGHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sawai Group Holdings Co stock appears to be undervalued.
The current stock price of $11.52 is trading 27.9% below its estimated GF Value™ of $15.98.
Key valuation signals for SWGHF:
3-Year EBITDA Growth Rate: 2.40% (near median its 10-year median of 2.40)
GF Value™: $15.98 vs. price of $11.52 (27.9% below fair value)
Industry Position: 72.7% below the Drug Manufacturers median (#509 of 813)
No single metric tells the full story. See the SWGHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sawai Group Holdings Co Ltd is engaged in providing management support or guidance to domestic and foreign companies engaged in businesses related to medical and healthcare services, such as the manufacture and sale of pharmaceutical products and medical equipment, as well as various businesses incidental or related to the same.
53GF Score
Get the complete analysis for SWGHF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWGHF has been successfully added to your 
